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Background: Patients with diabetes mellitus have increased risk of cardiovascular disease and worse outcomes after myocardial infarction (MI). 
Results from trials examining the cardiovascular safety of individual oral glucose-lowering drugs (GLD) after MI are conflicting.
Methods: All patients aged 30 years or older receiving GLD and admitted with Non-ST elevation MI (Non-STEMI) in the period 1997 to 2006 
were identified by individual-level-linkage of nationwide registries of hospitalizations and drug dispensing from pharmacies. Multivariate Cox 
regression models were used to assess differences in the composite endpoint of non-fatal MI and cardiovascular death between individual GLD, after 
adjustments for confounding variables, i.e., age, sex, calendar year, comorbidity and concomitant pharmacotherapy.
Results: The study comprised 9876 users of GLD admitted with Non-STEMI. The mean age at admission was 72.3 years and 56.5% of patients were 
men. A total of 3649 received sulfonylurea monotherapy and 711 received metformin alone at the time of admittance. The average length of follow-
up was 2.2 (SD 2.6) years. Increased risk of non-fatal MI and cardiovascular death was found for the sulfonylureas glimepiride (hazard ratio [HR] 
1.19; 95% confidence interval [CI] 1.07-1.33), glyburide (HR 1.38; CI 1.17-1.47), glipizide (HR 1.23; CI 1.11-1.42), and tolbutamide (HR 1.18; CI 
1.04-1.35), compared to metformin monotherapy. Gliclazide was not associated with increased risk (HR 1.03; CI 0.87-1.21).
Conclusion: In patients with diabetes mellitus admitted with Non-STEMI, all investigated sulphonylurea drugs apart from gliclazide were 
associated with increased cardiovascular risk, compared with metformin alone. Further studies on cardiovascular safety of individual GLDs are 
warranted.
